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Summary
Background Human African trypanosomiasis (HAT) is a life-threatening infection aﬀ ecting rural populations in sub-
Saharan Africa. Large-scale population screening by antibody detection with the Card Agglutination Test for 
Trypanosomiasis (CATT)/Trypanosoma brucei (T b) gambiense helped reduce the number of reported cases of 
gambiense HAT to fewer than 10 000 in 2011. Because low case numbers lead to decreased cost-eﬀ ectiveness of such 
active screening, we aimed to assess diagnostic accuracy of a rapid serodiagnostic test (HAT Sero-K-SeT) applicable in 
primary health-care centres.
Methods In our case-control study, we assessed participants older than 11 years who presented for HAT Sero-K-SeT 
and CATT/T b gambiense at primary care centres or to mobile teams (and existing patients with conﬁ rmed disease 
status at these centres) in Bandundu Province, DR Congo. We deﬁ ned cases as patients with trypanosomes that had 
been identiﬁ ed in lymph node aspirate, blood, or cerebrospinal ﬂ uid. During screening, we recruited controls without 
previous history of HAT or detectable trypanosomes in blood or lymph who resided in the same area as the cases. We 
assessed diagnostic accuracy of three antibody detection tests for gambiense HAT: HAT Sero-K-SeT and 
CATT/T b gambiense (done with venous blood at the primary care centres) and immune trypanolysis (done with 
plasma at the Institute of Tropical Medicine, Antwerp, Belgium).
Findings Between June 6, 2012, and Feb 25, 2013, we included 134 cases and 356 controls. HAT Sero-K-SeT had a 
sensitivity of 0·985 (132 true positives, 95% CI 0·947–0·996) and a speciﬁ city of 0·986 (351 true negatives, 0·968–0·994), 
which did not diﬀ er signiﬁ cantly from CATT/T b gambiense (sensitivity 95% CI 0·955, 95% CI 0·906–0·979 [128 true 
positives] and speciﬁ city 0·972, 0·949–0·985 [346 true negatives]) or immune trypanolysis (sensitivity 0·985, 
0·947–0·996 [132 true positives] and speciﬁ city 0·980, 0·960–0·990 [349 true negatives]).
Interpretation The diagnostic accuracy of HAT Sero-K-SeT is adequate for T b gambiense antibody detection in local 
health centres and could be used for active screening whenever a cold chain and electricity supply are unavailable and 
CATT/T b gambiense cannot be done.
Funding European Commission FP7 (NIDIAG, Grant Agreement 260260) and WHO Control of Neglected Tropical 
Diseases, Innovative and Intensiﬁ ed Disease Management.
Copyright © Büscher et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Human African trypanosomiasis (HAT), or sleeping 
sickness, is a life-threatening neglected tropical infection 
aﬀ ecting rural populations in sub-Saharan Africa.1 In 
west and central Africa, the chronic form of sleeping 
sickness is caused by Trypanosoma brucei (T b) gambiense. 
In eastern and southern Africa, a more fulminant form 
is caused by T b rhodesiense.2 Infection starts with the bite 
of an infected tsetse ﬂ y (Glossina spp). The disease is 
characterised by two stages, consisting of a haemo-
lymphatic stage, with trypanosomes multiplying mainly 
in lymph and blood, which generally evolves into the 
second or meningoencephalitic stage in which the 
central nervous system becomes invaded. If left 
untreated, the infection is almost invariably fatal.3 
Treatment is possible but present drugs are unsatisfactory 
because of their toxicity, complex application, and 
cumbersome logistics.4,5
In the 1990s, T b gambiense HAT ravaged several west 
and central African countries. Thanks to the combined 
eﬀ orts of national control programmes, bilateral 
cooperation agencies, non-governmental organisations, 
and WHO, fewer than 10 000 new cases were reported 
in 2011 and elimination of HAT as a public health 
problem is now regarded as possible.6,7 One of the key 
factors leading to this success in HAT control was the 
adoption of a serodiagnostic test, the Card Agglutination 
Test for Trypanosomiasis (CATT/T b gambiense8) as a 
screening technique. CATT is a rapid serological test that 
allows screening of large populations for trypanosome-
speciﬁ c antibodies. Only those tests with a positive CATT 
result need then be subjected to time-consuming 
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parasitological examinations. However, the CATT test, 
which is distributed as 50 tests per vial, is designed for 
mass screening by specialised mobile teams and 
necessitates a cold chain for proper storage. It is therefore 
not appropriate for decentralised implementation in 
peripheral health facilities with few participants to screen 
on a daily basis, since opened vials have to be discarded 
after 24 h at ambient temperature and cold chain storage 
at 4°C is often not available because of intermittent 
electrical supply in HAT-endemic regions. With the 
steadily decreasing prevalence of HAT, cost-eﬀ ectiveness 
of active screening has diminished, and a subsequent 
reduction of budgets for screening of the population at 
risk has meant that not only has the role of the ﬁ xed 
health-care centres for diagnosis, care, and surveillance 
of HAT become more prominent, but also that the 
diagnostic techniques need to be adapted. Development 
of a highly speciﬁ c and sensitive individual rapid 
diagnostic test that is stable at ambient temperature and 
can be used after minimal training is therefore a research 
priority.2
We have previously reported on the development and 
proof-of-principle of a new rapid serodiagnostic test for 
gambiense sleeping sickness, called HAT Sero-K-SeT.9 
In this study, we aimed to assess the diagnostic accuracy 
of the HAT Sero-K-SeT on clinical samples from well 
characterised cases and endemic controls in DR Congo 
by comparison with an existing antibody detection test 
used in routine screening (CATT whole blood) and a 
sophisticated antibody assay used in reference 
laboratories (immune trypanolysis).
Methods
Study design and participants
Our case-control study was done in Bandundu Province, 
DR Congo. In 2011, the national control programme 
(Programme National de Lutte contre la Trypanosomiase 
Humaine Africaine [PNLTHA]) reported an overall 
prevalence of HAT of 0·18% in this province.10 
Participants were included in the HAT treatment centres 
of the cities of Masi Manimba, Kikwit, Masa Muna, 
Nvunda, and Kisalaboyi and during mobile team active 
screening campaigns in two health districts, 
Masi Manimba and Bandjow Moke.
All individuals older than 11 years who presented for 
HAT screening at one of these centres or mobile team 
sessions, and existing patients with known conﬁ rmed 
disease admitted to the treatment centres, were eligible 
for study enrolment. All cases were examined in the 
same way. The deﬁ nition of a case in this study was a 
patient with trypanosomes in lymph, blood, or 
cerebrospinal ﬂ uid, irrespective of disease stage. We 
deﬁ ned controls as individuals without previous history 
of HAT or detectable trypanosomes in blood and lymph, 
who were residing in the same area as the cases. Controls 
were people who presented for screening (not necessarily 
relatives or age-matched or sex matched) but in whom 
no parasites were detected. We excluded participants 
who provided less than 4 mL of blood for analysis.
The study received clearance from the Ethics 
Committees of the University of Antwerp, Belgium 
(11.43.5.795) and of the Ministry of Health, DR Congo 
(NGCOETH./002/2012). Participants or guardians 
provided written informed consent before enrolment. 
We obtained assent from children aged 12–18 years.
Procedures
The reference standard was conﬁ rmed presence of 
parasites detected through the combination of mini Anion 
Exchange Centrifugation Technique (mAECT) on whole 
blood and direct microscopic examination of lymph node 
aspirate and cerebrospinal ﬂ uid. Identiﬁ cation of 
trypanosomes in one test was suﬃ  cient to establish 
diagnosis of conﬁ rmed HAT. All consenting participants 
were ﬁ rst screened with the CATT/T b gambiense test (on 
blood taken from a ﬁ nger-prick test) and by cervical lymph 
node palpation, according to the national guidelines 
issued by the PNLTHA. Irrespective of the CATT whole 
blood result, 4 mL of venous blood was collected in 
heparinised tubes for parasitological examination in the 
mAECT.11 The remaining blood was used for testing in the 
HAT Sero-K-SeT and for preparation of plasma to be 
tested in immune trypanolysis. No direct microscopy was 
done. Lymph aspirate was collected and microscopically 
examined for trypanosomes from consenting participants 
who presented swollen cervical lymph nodes. Unless 
clinically contraindicated, patients with conﬁ rmed HAT 
(ie, those for whom trypanosomes were observed in the 
lymph node aspirate, blood, or both) underwent lumbar 
puncture to assess the disease stage before treatment was 
started. The lumbar puncture was also done, according to 
national guidelines, on some suspected cases without 
detectable parasites in blood and lymph but with clear 
serological and neurological evidence of HAT. For disease 
staging, we regarded 0–5 white blood cells per μL and no 
trypanosomes in cerebrospinal ﬂ uid as the ﬁ rst stage, and 
more than 5 white blood cells per μL with or without 
trypanosomes in cerebrospinal ﬂ uid as the second stage. 
Microscopy was done by experienced personnel, and 
presence of trypanosomes was always conﬁ rmed by a 
second microscopist. Because identiﬁ cation of 
trypanosomes in one test is suﬃ  cient to establish 
diagnosis of conﬁ rmed HAT, a few patients with HAT did 
not undergo all parasitological examinations (mAECT or 
lymph node ﬂ uid examination). Treatment was provided 
according to the national guidelines without reference to 
results obtained in the HAT Sero-K-SeT or immune 
trypanolysis testing.
HAT Sero-K-SeT (Coris BioConcept, Gembloux, 
Belgium) detects antibodies and can be done with plasma 
or whole blood. Blood cells are ﬁ ltered on the sample pad 
and only plasma migrates over the nitrocellulose 
membrane while reacting with the target antigens, in 
this case an equimolar mixture of T b gambiense variant 
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surface glycoproteins LiTat 1.3 and LiTat 1.5, and the 
conjugate. For this study, 30 μL of blood was dispensed 
in the sample application window followed by 85 μL of 
migration buﬀ er (ﬁ gure). After 15 min, the test result 
was read as positive if both the control and the test line 
were visible (even if very faint), negative if only the 
control line was visible, or invalid if the control line was 
not visible (in which case a new test was done). Each test 
was read by two independent readers who were masked 
to the microscopy results apart from those for patients 
with conﬁ rmed HAT, who were included at the treatment 
centres while waiting for the start of their treatment. At 
the start of the study, the test developers (PB and QG) did 
this reading during 2 weeks, which was subsequently 
continued by local health staﬀ  (trained by PB and QG).
All plasma specimens were preserved in liquid nitrogen 
for transfer to the Institut National de Recherche 
Biomédicale in Kinshasa and then to the Institute of 
Tropical Medicine in Antwerp, Belgium to be tested in 
immune trypanolysis as the reference test for speciﬁ c 
antibodies against T b gambiense VAT LiTat 1.3 and 
LiTat 1.5.12 Microscopic reading of the results of immune 
trypanolysis was done by experienced staﬀ , who were 
masked to other test results.
Statistical analysis
We calculated a sample size of 200 HAT cases would be 
needed to estimate the sensitivity of the HAT Sero-K-SeT 
within 5% and assuming a sensitivity of at least 85%. 
Conversely, we calculated a sample size of 350 controls 
would be needed to show a higher speciﬁ city of HAT 
Sero-K-SeT than of CATT while expecting a speciﬁ city of 
95% for HAT Sero-K-SeT and 90% for CATT. However, 
enrolment had to be stopped prematurely because the 
accrual rate of cases was much slower than was expected. 
All results were entered in an Excel database. We 
calculated sensitivities and speciﬁ cities with 95% 
binomial Wilson conﬁ dence intervals with Stata 10. We 
used the McNemar χ² test in Stata 10 to test diﬀ erences 
in sensitivity and speciﬁ city of the HAT Sero-K-SeT 
compared with CATT/T b gambiense and immune 
trypanolysis.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
We included participants between June 6, 2012, and 
Feb 25, 2013. We initially included 135 patients with HAT, 
although one participant was excluded from analysis 
because of missing parasitological results in the database. 
Thus, we included 134 conﬁ rmed cases in the analysis 
(58 [43%] male and 76 [57%] female), with a median age 
of 33·0 years (IQR 24·5–48·0). 64 patients with HAT 
were included at the treatment centres while waiting for 
the start of their treatment. 56 (42%) patients with HAT 
presented swollen cervical lymph nodes, with conﬁ rmed 
parasite presence in 42 (84%) of 50 participants who had 
their lymph node ﬂ uid tested for presence of parasites. 
Trypanosomes were detected on blood microscopy 
in 88 (83%) of 106 patients with HAT. 131 participants 
had lumbar punctures (three patients had no lumbar 
puncture for medical reasons such as pregnancy). We 
noted trypanosomes in the cerebrospinal ﬂ uid of 51 
(42%) of 122 patients (nine patients had missing 
parasitological cerebrospinal ﬂ uid results in database). 
14 patients with positive cerebrospinal ﬂ uid samples 
were negative for trypanosomes in blood and lymph 
analyses. 39 (32%) of 122 cases (nine had insuﬃ  cient 
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Figure: HAT Sero-K-SeT procedure
HAT=human African trypanosomiasis.
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results for staging in database) were in the ﬁ rst stage of 
the disease. We noted microﬁ laria in two cases on 
mAECT.
We included 363 participants as non-HAT controls, of 
whom seven were excluded from the analysis because of 
inconsistent or missing results from the database (four 
participants) or no plasma available for immune 
trypanolysis test (three participants). Thus, we 
included 356 controls in the analysis (144 [40%] male and 
212 [60%] female, with a median age of 29·0 years 
(IQR 21·0–42·0). We noted microﬁ lariae in the blood 
of 16 controls.
We had no discordant readings with HAT Sero-K-SeT 
between the two independent readers. On one occasion, 
the test line was scored as very faint by the two observers 
and the opinion of a third masked reader was sought, 
who conﬁ rmed the faint test line as positive. The table 
shows sensitivity and speciﬁ city of the three serological 
tests.
We noted no signiﬁ cant diﬀ erence in sensitivities or 
speciﬁ cities between HAT Sero-K-SeT versus CATT 
whole blood (p=0·16 for sensitivity and p=0·06 for 
speciﬁ city), CATT versus immune trypanolysis HAT 
(p=0·16 for sensitivity and p=0·44 for speciﬁ city), or HAT 
Sero-K-SeT versus immune trypanolysis (p=1·00 for 
sensitivity and p=0·53 for speciﬁ city). Of seven controls 
with positive results on immune trypanolysis (2%), only 
one tested seropositive in the ﬁ eld, on both CATT whole 
blood and in HAT Sero-K-SeT analyses.
Discussion
The high sensitivity (98·5%) and speciﬁ city (98·6%) we 
noted for HAT Sero-K-SeT on venous blood samples 
supports the level of diagnostic accuracy reported in a 
phase 1 trial with reconstituted blood samples and are 
much the same as reports for another rapid diagnostic 
test for gambiense sleeping sickness, the HAT SD 
Bioline.9,13 HAT Sero-K-SeT, CATT whole blood, and 
immune trypanolysis are very similar with regard to the 
antigens presented, because they are all based on native 
variant surface glycoprotein, with a combination of 
LiTat 1.3 and LiTat 1.5 for HAT Sero-K-SeT and immune 
trypanolysis and LiTat 1.3 only for CATT. In theory, the 
use of a single variant surface glycoprotein in CATT 
might lead to a lower sensitivity, which might be 
counterbalanced by exposure of other non-variant 
epitopes on the ﬁ xed reagent, which in turn could aﬀ ect 
speciﬁ city. Patients infected with trypanosomes that do 
not express these variant surface glycoproteins might not 
develop antibodies against the antigens in use, and 
remain negative in all three tests, but such patients are 
probably rare. Nevertheless, the diagnostic ability of all 
three serological tests was excellent in our assessment 
and did not diﬀ er signiﬁ cantly between groups.
Our study had limitations. To be able to enrol suﬃ  cient 
participants, about half of the cases were recruited in the 
treatment centres to which they were referred by a mobile 
team on the basis of an initially positive CATT/T b gambiense 
result. This strategy might have made us overestimate the 
sensitivity of the tests because it could have caused a 
selection bias towards the LiTat 1.3 antigen in cases. 
Moreover, because test readers were not masked to the 
microscopy results of these patients and although both 
readings were done independently, theoretically this 
approach could have led to improved rates of reading, 
especially for very faint test lines. The restricted 
geographical distribution of the participants in this study 
might be regarded as another limitation. However, this 
study site lies about 1000 km away from the HAT foci in 
East Kasai Province, DR Congo, from where the 
specimens used in the phase 1 assessment of the 
HAT Sero-K-SeT originated.9 We used a composite 
reference standard in this study, based on combined 
parasite detection results. Although this technique 
Panel: Research in context
Systematic review
We did not do a systematic review before this trial was 
started. Three rapid diagnostic tests for serodiagnosis of 
human African trypanosomiasis (HAT) have been 
described,5,14 but to our knowledge no phase 2 diagnostic trial 
of these tests has been reported in peer-reviewed journals.
Interpretation
Our trial showed the diagnostic accuracy of HAT Sero-K-SeT, 
an individual rapid serodiagnostic test for HAT in a 
case-control study done in tropical ﬁ eld conditions in DR 
Congo (the country that reports most cases of the infection). 
The results suggest that the choice of a screening test for this 
disease can be based on the test format, because diagnostic 
accuracy of HAT Sero-K-SeT was not diﬀ erent from other test 
formats that are more suitable for mass screening and for 
reference testing. HAT Sero-K-SeT facilitates detection at 
peripheral health facilities and might contribute to elimination 
of HAT.
Number of patients testing positive Sensitivity Number of controls testing negative Speciﬁ city
HAT Sero-K-SeT 132/134 0·985 (95% CI 0·947–0·996) 351/356 0·986 (95% CI 0·968–0·994)
CATT whole blood 128/134 0·955 (95% CI 0·906–0·979) 346/356 0·972 (95% CI 0·949–0·985)
Immune trypanolysis 132/134 0·985 (95% CI 0·947–0·996) 349/356 0·980 (95% CI 0·960–0·990)
No missing or indeterminate results were noted for any test. CATT=Card Agglutination Test for Trypanosomosis. HAT=Human African trypanosomiasis.
Table: Sensitivity and speciﬁ city of the three serological tests, with combined parasitology as a reference
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increases the sensitivity of the reference standard, we 
acknowledge it might not reach 100%. Therefore, our 
control group might have contained some positive (but 
undetected) cases of HAT, resulting in a relative 
underestimation of the serological test speciﬁ city.
Our results suggest that choice of a screening test for 
HAT can be based on the format that ﬁ ts the purpose 
best. For example, CATT/T b gambiense seems most 
suitable for active case detection (ie, large-scale 
screening) with mobile teams that have access to 
electricity from a generator, a car battery, or a solar 
panel, whereas HAT Sero-K-SeT seems well adapted for 
use in peripheral  health centres (ie, centres with a low 
number of suspected cases and no or intermittent 
electricity supply) or for active case detection in less 
accessible locations when CATT/T b gambiense cannot 
be done for logistical reasons (panel). Immune 
trypanolysis requires more sophisticated equipment 
and skills, and its use is therefore restricted to centrally 
located laboratories, which can use the test to process 
large batches of samples from epidemiological surveys 
or surveillance activities.
The next step in the development of the HAT Sero-K-SeT 
will be assessment of diagnostic accuracy in a prospective 
study on a series of patients presenting at health centres 
with suspected HAT. Such a phase 3 diagnostic trial is 
already ongoing in DR Congo. Rapid diagnostic tests 
such as HAT Sero-K-SeT oﬀ er an opportunity to simplify 
disease detection at the peripheral health facilities and 
will become valuable methods to reach the goal of HAT 
elimination.15
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